{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:34:19Z","timestamp":1730349259415,"version":"3.28.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77072-8","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T20:01:53Z","timestamp":1730318513000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II study of uPAR-PET\/CT for staging of primary breast cancer in comparison with ultrasound and fine needle biopsies"],"prefix":"10.1038","volume":"14","author":[{"given":"Marie \u00d8bro","family":"Fosb\u00f8l","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esben Andreas","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malene","family":"Brandt-Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Loft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Kiil","family":"Berthelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tove Filtenborg","family":"Tvedskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Kroman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Francis","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"von Benzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"77072_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/0284186X.2017.1406138","volume":"57","author":"K Hamran","year":"2018","unstructured":"Hamran, K., Langhans, L., Vejborg, I., Tvedskov, T. F. & Kroman, N. The accuracy of preoperative staging of the axilla in primary breast cancer: A national register based study on behalf of Danish Breast Cancer Group (DBCG). Acta Oncol. 57, 162\u2013166 (2018).","journal-title":"Acta Oncol."},{"key":"77072_CR2","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/annonc\/mds002","volume":"23","author":"M Bernsdorf","year":"2012","unstructured":"Bernsdorf, M. et al. Preoperative PET\/CT in early-stage breast cancer. Ann. Oncol. 23, 2277\u20132282 (2012).","journal-title":"Ann. Oncol."},{"key":"77072_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso, F. et al. Early breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1194\u20131220 (2019).","journal-title":"Ann. Oncol."},{"key":"77072_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.semnuclmed.2022.05.001","volume":"52","author":"D Groheux","year":"2022","unstructured":"Groheux, D. FDG-PET\/CT for primary staging and detection of recurrence of breast cancer. Semin. Nucl. Med. 52, 508\u2013519 (2022).","journal-title":"Semin. Nucl. Med."},{"key":"77072_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","volume":"75","author":"MJ Duffy","year":"2017","unstructured":"Duffy, M. J. et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer. 75, 284\u2013298 (2017).","journal-title":"Eur. J. Cancer"},{"key":"77072_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of Cancer: New dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov"},{"key":"77072_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.116.178970","volume":"58","author":"D Skovgaard","year":"2016","unstructured":"Skovgaard, D. et al. Safety, dosimetry and tumor detection ability of 68 Ga - NOTA - AE105 - a novel radio ligand for uPAR PET imaging : First-in-humans study. J. Nucl. Med. 58, 379\u2013386 (2016).","journal-title":"J. Nucl. Med."},{"key":"77072_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/med.10054","volume":"24","author":"CE De Bock","year":"2004","unstructured":"De Bock, C. E. & Wang, Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24, 13\u201339 (2004).","journal-title":"Med. Res. Rev."},{"key":"77072_CR9","first-page":"1079","volume":"10","author":"J Gr\u00f8ndahl-Hansen","year":"1995","unstructured":"Gr\u00f8ndahl-Hansen, J. et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast Cancer. Clin. Cancer Res. 10, 1079\u20131087 (1995).","journal-title":"Clin. Cancer Res."},{"key":"77072_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1160\/TH05-01-0054","volume":"93","author":"K Dan\u00f8","year":"2005","unstructured":"Dan\u00f8, K. et al. Plasminogen activation and cancer. Thromb. Haemost. 93, 676\u2013681 (2005).","journal-title":"Thromb. Haemost"},{"key":"77072_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1054\/bjoc.2001.1867","volume":"85","author":"JH de Witte","year":"2001","unstructured":"de Witte, J. H. et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br. J. Cancer. 85, 85\u201392 (2001).","journal-title":"Br. J. Cancer"},{"key":"77072_CR12","first-page":"636","volume":"60","author":"JA Foekens","year":"2000","unstructured":"Foekens, J. A. et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636\u2013643 (2000).","journal-title":"Cancer Res."},{"key":"77072_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7150\/thno.7323","volume":"4","author":"AM LeBeau","year":"2014","unstructured":"LeBeau, A. M. et al. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 4, 267\u2013279 (2014).","journal-title":"Theranostics"},{"key":"77072_CR14","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-12-3526","volume":"73","author":"AM Le Beau","year":"2013","unstructured":"Le Beau, A. M. et al. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 73, 2070\u20132081 (2013).","journal-title":"Cancer Res."},{"key":"77072_CR15","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.24166","volume":"124","author":"M Illemann","year":"2009","unstructured":"Illemann, M. et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int. J. Cancer. 124, 1860\u20131870 (2009).","journal-title":"Int. J. Cancer"},{"key":"77072_CR16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0002-9440(10)64637-8","volume":"157","author":"E Dublin","year":"2000","unstructured":"Dublin, E., Hanby, A., Patel, N. K., Liebman, R. & Barnes, D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am. J. Pathol. 157, 1219\u20131227 (2000).","journal-title":"Am. J. Pathol."},{"key":"77072_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/jcm10071543","volume":"10","author":"ML Boulc\u2019h","year":"2021","unstructured":"Boulc\u2019h, M. L., Gilhodes, J., Steinmeyer, Z., Moli\u00e8re, S. & Mathelin, C. Pretherapeutic imaging for axillary staging in breast cancer: A systematic review and meta-analysis of ultrasound, MRI and FDG PET. J. Clin. Med. 10, 1543 (2021).","journal-title":"J. Clin. Med."},{"key":"77072_CR18","doi-asserted-by":"crossref","unstructured":"Stachs, A. et al. Accuracy of Axillary Ultrasound in Preoperative Nodal Staging of Breast Cancer - Size of Metastases as Limiting Factor. Springerplus  29:2350 (2013)","DOI":"10.1186\/2193-1801-2-350"},{"key":"77072_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker, M. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 15, 1303\u20131310 (2014).","journal-title":"Lancet Oncol."},{"key":"77072_CR20","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.clbc.2021.09.004","volume":"22","author":"N LeVasseur","year":"2022","unstructured":"LeVasseur, N. et al. Impact of the 21-Gene recurrence score assay on the treatment of Estrogen Receptor-Positive, HER2-Negative, breast Cancer patients with 1\u20133 positive nodes: A prospective clinical utility study. Clin. Breast Cancer. 22, e74\u2013e79 (2022).","journal-title":"Clin. Breast Cancer"},{"key":"77072_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart, M. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: Updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22, 476\u2013488 (2021).","journal-title":"Lancet Oncol."},{"key":"77072_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/ijc.11488","volume":"107","author":"A Hemsen","year":"2003","unstructured":"Hemsen, A. et al. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int. J. Cancer. 107, 903\u2013909 (2003).","journal-title":"Int. J. Cancer"},{"key":"77072_CR23","first-page":"869","volume":"24","author":"R Hildenbrandt","year":"2009","unstructured":"Hildenbrandt, R. et al. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: Prognostic impact. Histol. Histopathol. 24, 869\u2013877 (2009).","journal-title":"Histol. Histopathol"},{"key":"77072_CR24","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7150\/thno.12956","volume":"5","author":"M Persson","year":"2015","unstructured":"Persson, M. et al. First-in-human uPAR PET: Imaging of Cancer aggressiveness. Theranostics. 5, 1303\u20131316 (2015).","journal-title":"Theranostics"},{"key":"77072_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.116.180430","volume":"58","author":"CB Johnbeck","year":"2017","unstructured":"Johnbeck, C. B. et al. Head-to-Head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET\/CT: A prospective study of 59 patients with neuroendocrine tumors. J. Nucl. Med. 58, 451\u2013457 (2017).","journal-title":"J. Nucl. Med."},{"key":"77072_CR26","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2967\/jnumed.121.263177","volume":"63","author":"EA Carlsen","year":"2022","unstructured":"Carlsen, E. A. et al. Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR-Targeted therapy. J. Nucl. Med. 63, 1371\u20131377 (2022).","journal-title":"J. Nucl. Med."},{"key":"77072_CR27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/diagnostics11061087","volume":"11","author":"M\u00d8 Fosb\u00f8l","year":"2021","unstructured":"Fosb\u00f8l, M. \u00d8. et al. uPAR PET\/CT for Prognostication and Response Assessment in patients with metastatic castration-resistant prostate Cancer undergoing Radium-223 therapy: A prospective phase II study. Diagnostics (Basel). 11, 1087 (2021).","journal-title":"Diagnostics (Basel)"},{"key":"77072_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.121.262866","volume":"63","author":"LM Ris\u00f8r","year":"2022","unstructured":"Ris\u00f8r, L. M. et al. Prognostic value of urokinase-type plasminogen activator receptor PET\/CT in Head and Neck Squamous Cell Carcinomas and comparison with 18F-FDG PET\/CT: A single-center prospective study. J. Nucl. Med. 63, 1169\u20131176 (2022).","journal-title":"J. Nucl. Med."},{"key":"77072_CR29","first-page":"254","volume":"62","author":"M\u00d8 Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l, M. \u00d8. et al. Urokinase plasminogen activator receptor (uPAR) PET\/MRI of prostate cancer for non-invasive evaluation of aggressiveness: A prospective phase II clinical trial comparing with Gleason Score. J. Nucl. Med. 62, 254\u2013359 (2020).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77072-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77072-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77072-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T20:03:27Z","timestamp":1730318607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77072-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77072"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77072-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JM and AK are inventors on a patent on the matter of uPAR PET (WO 2014086364) and co\u2010founders of the company Curasight, which has acquired rights to uPAR-PET technology. Curasight supported the investigator-initiated study financially.The remaining authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The remaining authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26183"}}